• Company
  • News
  • Investors
  • Contacts
  • Careers
PPTPPTlogo-mobilePPT
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Generic peptides
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Cosmetic
  • Individualized Peptides
  • Oligos
  • Services
    • GMP Compliance
    • Pre-GMP development
    • Production
    • Quality Assurance
    • Quality control
    • Regulatory Support
  • Generic peptides
  • Commercial Manufacturing
    • Commercial products at PolyPeptide
    • Late stage development
    • Process development and optimization
    • Capacity and Capabilities
  • Custom R&D
    • Custom Research Grade Peptides
    • Radiolabeled peptide
  • Cosmetic
  • Individualized Peptides
  • Oligos
  • Home
  • News
  • Business news
  • Therapeutic indications for the PolyPeptide Group pipeline projects 2020

Therapeutic indications for the PolyPeptide Group pipeline projects 2020

28 January 2021
Business news

PolyPeptide Group is proud to report double-digit growth for its pipeline projects.

PolyPeptide Group maintained a strong and healthy pipeline that has gained a significant growth in 2020. This growth in Pipeline Projects reflects the growth in peptide therapeutics market and emphasizes the importance of peptides in drug and vaccine development.

Double-digit growth in pipeline projects was driven by a wide variety of development programs including projects related to COVID-19 therapies and vaccines, as well as new projects focused on Oncology, and Cardiovascular & Metabolic Disorders, among others.

As a Global Leader in Peptide API Manufacturing & Development, the PolyPeptide Group is a trusted partner in several peptide-based projects aimed at therapies and vaccines for the COVID-19 pandemic.

Back to news

Related posts

9 November 2022

FluoGuide reaches milestone with FG001 for phase III clinical supply


Read more
28 June 2022

PolyPeptide wins Malmö Life Science Business Award


Read more
22 December 2021

Efficient and sustainable solutions for large scale peptide manufacturing


Read more

Polypeptide Group

INFO

COMPANY
LEADERSHIP
CONTACTS
CAREERS

NEWS

LATEST NEWS
SIGN UP FOR NEWS
EVENTS

SOCIALS

LINKEDIN
YOUTUBE
© Confidentiality 2021 PolyPeptide Group • Cookie management • Personal data • Sitemap • Confidentiality policy
      By clicking “Accept”, you consent to the use of ALL the cookies on our website . However you may visit Cookie Settings to provide a controlled consent.
      Cookie settingsACCEPT
      Privacy & Cookies Policy

      Privacy Overview

      You can enable or disable your consent for each category of cookie.

      More information on the collection of personal data
      Necessary
      Always Enabled

      The necessary cookies help to make a website usable by enabling basic functions such as page navigation and access to secure areas of the website. The website cannot function properly without these cookies.

      Advertisement

      Marketing cookies are used to track visitors through websites. The goal is to display ads that are relevant and interesting to the individual user and therefore more valuable to third-party publishers and advertisers.

      Analytics

      Statistical cookies help website owners, through the anonymous collection and communication of information, to understand how visitors interact with websites.

      Performance

      Preferences cookies allow a website to retain information that changes the way the site behaves or displays, such as your preferred language or the region in which you are located.

      Save & Accept